As an investor in Elan (the company which discovered Antegren and is partnering with Biogen on development), I am biased. However, it is scary to read about the mis-information being spouted on this board from people like "Harry Z" and "Guest". The current market for MS drugs is about $5 billion per annum and the existing players are going to do their best to spread dis-information so that you stay with your existing drug. Of course, one should not take my word for it either. My suggestion to you is not to believe anything you read about Antegren unless there is a web link to a legitimate site.
Following is a summary of Phase II Antegren results as printed in the New England Journal of Medicine showing 90% reduction in lesions and 50% reduction in relapses, with side effects that WERE NO DIFFERENT THAN PLACEBO:
Expected cost of Antegren is likely to be higher than Rebif ($14k per year) and most analysts are guessing between $16 thousand to $20 thousand per year. Jim Mullen, the CEO of Biogen said the following: "The highest price is currently the high-dose Rebif, which is now selling at a 25 percent to 30 percent premium for a very small increase in effect," he said. "I think the market will pay for much better efficacy. No decision on pricing has been made yet, he said."
FYI, I would not worry about cost in the sense that Biogen and Elan will not put a price on the drug which the insurance companies will refuse to pay. They are talking with the insurance companies currently and will price the drug when Antegren receives FDA approval.
http://boston.bizjournals.com/boston/st ... ily19.html
Between now and the expected approval date (given 6 month Fast Track, the FDA is supposed to respond by Nov 25th), there is going to be a lot of outsiders (of which I am one) that are willing to spend time on MS boards to provide the "truth" about Antegren. Please remember that no one in the public domain knows the Phase III results for Antegren. The end of the two-year Phase III will occur in the next few weeks. Elan and Biogen filed with the FDA for approval based on the interim one year data at the request of the FDA. However, also at the request of the FDA, the companies declined to release the one-year interim data in order to ensure that the results from the two year study are not tainted.
Biogen and Elan have said that they will release the one-year interim data for the Phase III Antegren study upon approval by the FDA. It is likely to take another six months for the company to collate, analyze, and release the two-year data.
With regards to whether Antegren will be used alone, or in combination, that is still a question. The CEO of Elan has said that it is likely to be a monotherapy but that opinion is not universally shared.
Obviously, I have a monetary interest in this, but I hope that Antegren is successful in providing an effective therapy for MS. Good luck to you all.